b'uFromPage 8Continuation of Chronic BuprenorphineThisstudysuggeststhatbuprenorphinecanbe A total of 70 of 259 screened patients78.6% ofsafely continued in most patients with various sources whom had an OUD diagnosismet inclusion crite- of pain irrespective of the initial diagnosis of chronic ria. While 84.3% presented to the emergency depart- pain or OUD, Jones said. ment, 15.7% underwent surgical procedures.She said to her knowledge, the review is the first to The primary outcome was to characterize buprenor- characterize acute and postsurgical pain management phine treatment strategies based on the change in totalin a veteran population on chronic buprenorphine or daily dose between the index data and discharge date,buprenorphine/naloxone therapy. Jones said. The total daily dose of buprenorphine/nal- She added that future large, prospective studies are oxone from index date to discharge was continued inneeded to identify the best strategies and clear recom-90% of cases, increased in 2.9% of cases, decreasedmendations on how to most effectively manage acute in 1.4% of cases and discontinued in 5.7% of cases.pain in patients receiving buprenorphine products. Based on the outcomes of this review, the continu- 1Jones, A. C., Tillman, F., 3rd, Kahlon, C., Seys, R., & Pepin, M. ation of chronic buprenorphine therapy was the most(2024). Characterizing acute and postsurgical pain management in common practice observed, said Jones, noting thatpatients receiving buprenorphine or buprenorphine/naloxone. Journal of the American Pharmacists Association : JAPhA, 102035. Advance safety concerns, such as representation for acute pain,online publication. https://doi.org/10.1016/j.japh.2024.02.008OUD relapse, overdose or mortality, were not clini-cally meaningful.Source: Characterizing acute and postsurgical pain management in patients receiving buprenorphine or buprenorphine/naloxone. Journal of the American Pharmacists Association : JAPhA, 102035. Advance online publication. https://doi.org/10.1016/j.japh.2024.02.00810'